A large proportion of our patients (85.5%) received tocilizumab (anti-interleukin-6 receptor) according to our hospital protocol treatment for COVID-19 patients (pneumonia with bilateral involvement associated with elevated interleukin-6 and C-reactive protein, requiring oxygen therapy). This evidence concerns the gene IL6R and COVID-19.